Keros faces make-or-break DMD launch window in Q2

Keros is now a post-PAH-failure rebuild story centered on rinvatercept. The nearest credible stock-moving catalyst is operational: initiation of the planned Phase 2 DMD trial in Q2 2026. With cash runway into 2028, low financing pressure, depressed valuation near cash/book, and a damaged but still tradable sentiment base, a confirmed DMD Phase 2 start could trigger a relief/rerating move. The setup is attractive but still speculative because this is an execution catalyst, not efficacy data.

Keros Therapeutics is a clinical-stage biotech that has effectively reset around rinvatercept (KER-065) after the collapse of its prior PAH thesis. That prior failure remains an overhang, but the company has since narrowed focus, preserved a strong balance sheet, and repositioned rinvatercept as the lead value driver in neuromuscular disease, especially Duchenne muscular dystrophy and later ALS. The most relevant near-term issue for investors is not commercialization or revenue growth, but whether management can execute on the promised next step: starting the DMD Phase 2 study in Q2 2026. Rinvatercept already has Phase 1 healthy-volunteer data showing target engagement and body-composition effects supportive of the mechanism, and management reinforced in March 2026 that its focus remains advancing the asset into two Phase 2 programs. However, the stock likely needs more than scientific rationale; it needs proof that Keros can actually move the program forward on schedule after the prior corporate disruption. That makes the DMD Phase 2 initiation the cleanest near-term catalyst. The stock is trading at a depressed level relative to historical prices and around/below book and cash-heavy valuation metrics, which can amplify upside if the company delivers a visible execution milestone. At the same time, investors should not expect a full restoration of the old premium because the PAH failure damaged credibility and rinvatercept still lacks patient efficacy data in DMD or ALS. So the likely move is a relief rally and partial rerating, not a return to prior cycle highs. ALS-related progress is real but more likely a second-half 2026 story tied to trial design and regulatory engagement through the Healey collaboration. That is less immediate and less likely to drive the next breakout than a hard DMD trial-start announcement. Overall, KROS looks like a speculative event-driven turnaround setup where the next meaningful upside window is tied to confirmation that the DMD Phase 2 program has officially begun.